Sino Biological
Sino Biological, an international reagent supplier and service provider, specializes in recombinant protein production and antibody development. All of the products are independently developed and produced, including recombinant proteins, antibodies and cDNA. Sino Biological is the researchers' one-stop technical services shop for the advanced technology platforms they need to make advancements and offers pre-clinical production technology services for monoclonal antibody drug candidates.
Sino Biological is a global leading provider of biological research reagents and related contract research services. The company offers a vast portfolio of around 9,000 recombinant proteins, 14,000 antibodies, 49,000 genes and multiple serum-free mammalian cell culture media products. These reagents are used by over 9,000 customers, from pharmaceutical and biotechnology companies to research institutions, in over 90 countries and regions worldwide. Sino Biological’s proprietary technology platforms also enable customized end-to-end solutions for customers with complex protein and antibody needs. Sino Biological’s team is continuously growing and currently has over 1,000 members worldwide. In recent years, the company has expanded to over 355,000 square feet, including 215,000 square feet of R&D and production facilities and over 53,000 square feet of good manufacturing practice (GMP)-level manufacturing workshops and laboratories, where over 2,000 new protein and antibody products are developed every year. The company has also achieved ISO9001, ISO13485, CNAS, CMA certification and GMP compliance certification. The company’s ProvirTM reagent collection is the world’s leading viral antigen bank, featuring thousands of antigens and antibodies and covering a wide range of viral types including influenza, respiratory syncytial virus (RSV) and coronavirus strains. Sino Biological aims to advance life science and improve human health through the provision of superior quality research reagents and contract research organization (CRO) services. They will continue to develop new products to address the unmet needs and demands from today’s biomedical research community.
Find out more ›